Last reviewed · How we verify

Nebulized lidocaine and dexmedetomidine

Ain Shams University · FDA-approved active Small molecule

Nebulized lidocaine provides local anesthesia of the airway while dexmedetomidine acts as a selective alpha-2 adrenergic agonist to produce sedation and analgesia.

Nebulized lidocaine provides local anesthesia of the airway while dexmedetomidine acts as a selective alpha-2 adrenergic agonist to produce sedation and analgesia. Used for Airway anesthesia and sedation for intubation procedures, Sedation and analgesia during bronchoscopy and airway manipulation.

At a glance

Generic nameNebulized lidocaine and dexmedetomidine
Also known asCombined lidocaine and dexmedetomidine group
SponsorAin Shams University
Drug classLocal anesthetic and sedative-analgesic combination
TargetVoltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia and critical care
PhaseFDA-approved

Mechanism of action

Lidocaine blocks sodium channels in nerve fibers, numbing the respiratory tract to reduce cough and airway discomfort. Dexmedetomidine binds to alpha-2 adrenergic receptors in the central nervous system, producing sedation, analgesia, and anxiolysis while maintaining airway reflexes. The combination is used to facilitate airway procedures and reduce patient discomfort during intubation or bronchoscopy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: